Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA Has Slim Advisory Committee Schedule – A Sign Of Things Not To Come?

Executive Summary

Agency has scheduled only two advisory committee meetings in 2017; does it indicate the agency plans to conduct fewer meetings going forward?


Related Content

FDA's Savings Machine: The White Oak Conference Room
Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore
Roche’s Highly Anticipated Ocrelizumab Delayed By Manufacturing Issues
Neurocrine Gets First Drug For Tardive Dyskinesia To FDA
Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?
Samsung Bioepis Taps Infliximab As Its US Biosimilar Pioneer
Duchenne Group's Presentation Is Milestone For Patient Involvement
Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade
User Fee Goal Dates
Pending Biosimilars


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts